Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.
创建时间：
2017-04-15
